PharmaTher Announces Positive Results from Study of KETABET™ for Depression
June 07, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
KETABET™ (Ketamine and Betaine) shown effectiveness as measured by the Clinician Administered Dissociative States Scale Study results are adequate to give an effect size in powering a...
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO
May 25, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher aims to become a leader in specialty...
PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs
May 05, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, May 05, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce...
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update
April 25, 2022 17:06 ET
|
PharmaTher Holdings Ltd.
Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable...
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs
April 12, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, April 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to...
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease
March 23, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well tolerated with no serious adverse events reported...
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation
February 16, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce...
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus
February 01, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce...
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS
January 12, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of...
PharmaTher Announces Publication of Research Data for KETABET™
January 04, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
Second published study to demonstrate the potential therapeutic utility and mechanism of action of KETABET™ (patented combination of ketamine and betaine) in models of depression Repeated use of...